Table 1.
EORTC metabolic response group definitions.
Fig 1.
Baseline PET with 5 target lesions (EORTC).
Blue spots corresponding to target lesions.
Fig 2.
Follow up PET with new measures of the same 5 target lesions (EORTC).
Blue spots corresponding to target lesions.
Table 2.
Summarised results of EORTC evaluation example.
Table 3.
PERCIST metabolic response group definitions.
Fig 3.
Baseline PET with a single target lesion (PERCIST).
Blue spot corresponding to the lesion having the highest SULpeak (target lesion). As shown on this image the highest SULpeak target is located on the left lobe of the liver.
Fig 4.
Follow up PET with a different location of the highest SULpeak target lesion (PERCIST).
Blue spot corresponding to the lesion having the highest SULpeak (target lesion). This follow up scan having a different target lesion, now located on the right lobe of the liver.
Table 4.
Summarised results of PERCIST evaluation example.
Table 5.
Patient characteristics.
Table 6.
Agreement between EORTC criteria and PERCIST (reader 1).
Table 7.
Agreement between EORTC criteria and PERCIST (reader 2).
Table 8.
Agreement and corresponding kappa coefficient between readers for EORCT and PERCIST.
Table 9.
Reasons for disagreement between EORTC criteria and PERCIST (reader 1).
Table 10.
Number of deaths during follow up depending on metabolic response according to EORCT and PERCIST.
Fig 5.
Overall survival stratified by metabolic response according to EORTC criteria (A) and PERCIST (B).
Fig 6.
Overall survival stratified by metabolic response (complete or non-complete) according to EORTC criteria (A) and PERCIST (B).
Fig 7.
Overall survival stratified by metabolic response (complete or non-complete) according to EORTC criteria (A) and PERCIST (B) in patients with luminal breast cancer (phenotype with the best prognosis during at the time of the study).
Table 11.
Cox regression univariate and multivariate analysis for prediction of death (reader 1).
Table 12.
Summary of EORCT and PERCIST evaluation methods.